LB-GABA对抗肥胖的作用
Hyein Han1, Gunju Song1, Jongwon Kim1
1Department of Food Science and Biotechnology, College of Life Science, CHA University, Seongnam 13488, Republic of Korea.
International journal of molecular sciences
|May 7, 2025
概括
乳杆菌大肠发酵的胺黄油酸 (LB-GABA) 通过抑制脂肪积累和促进脂肪分解,有效地对抗肥胖. 这种益生菌化合物还刺激白色脂肪组织的色,增加能量消耗.
科学领域:
- 代谢研究的研究.
- 脂肪组织生物学 脂肪组织生物学
- 微生物组与宿主之间的相互作用
背景情况:
- 肥胖源于能量代谢失衡,与代谢综合征有关.
- 白色脂肪组织 (WAT) 和棕色脂肪组织 (BAT) 调节能量平衡.
- 减肥策略需要抑制脂质积累并促进脂肪组织色.
研究的目的:
- 调查如何乳杆菌大发酵的胺黄油酸 (LB-GABA) 预防肥胖.
- 确定LB-GABA是否会在WAT中诱导脂解和色.
- 阐明LB-GABA抗肥胖作用背后的分子机制.
主要方法:
- 利用3T3-L1脂肪细胞研究LB-GABA的作用.
- 在关键信号通路中分析蛋白质表达的Western blotting.
- 对WAT进行了显微镜分析,以评估脂肪细胞形态和脂质滴滴含量.
主要成果:
- LB-GABA显著抑制了脂肪生成和脂质生成,抑制了脂质的积累.
- 显微镜分析显示,在LB-GABA治疗后,脂肪细胞大小和脂质滴滴数量减少.
- 西部斑点分析证实LB-GABA增强了脂解,并激活了PKA通路,促进了UCP1-介导的WAT棕色化.
结论:
- 通过调节脂质代谢,LB-GABA表现出抗肥胖作用.
- 通过WAT棕色化和脂解,LB-GABA促进了能源消耗.
- 这些发现突出了LB-GABA作为肥胖管理的潜在治疗剂.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
109
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
109
Hormonal Regulation
43.0K
Hormones regulate a significant portion of digestion through activation of the neuroendocrine system. The neuroendocrine system of digestion contains many different hormones all with multiple functions that are both, directly and indirectly, involved in digestion.
43.0K
Antiepileptic Drugs: GABAergic Pathway Potentiators
260
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
260
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
116
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
116
Regulation of Food Intake
148
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
148
Glucagon-like Receptor Agonists
266
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
266


